Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator th...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

AllinDeyra Oct. 4 at 7:52 PM

$ALDX another 100% and we are back at around 12 usd 😉

0 · Reply

TheGodsMustBeCrazy Oct. 3 at 8:56 PM

$ALDX shorts are about to get a rude awakening.

1 · Reply

Traderjoe1911 Oct. 3 at 8:24 PM

$ALDX Just here to remind everyone what we’re looking forward to OUTSIDE of Reproxalap’s December decision. - ADX-2191: Phase 3 is ongoing, phase 3 results to follow. - ADX-629: Phase 2 topline results for Sjögren-Larsson Syndrome AND Moderate Alcoholic Hepatitis expected in 2025. -NDAs for ADX-631/246 AND ADX-743 expected in 2025. Even if only a few of these are hits, Christmas may come early (or at least on time) this year. Set it and forget it until you’re hanging ornaments on the tree.

2 · Reply

AllinDeyra Oct. 3 at 8:06 PM

$ALDX breaking... 6,5 USD soon..back to the 6-8 corridor

0 · Reply

Milanfinest Oct. 3 at 8:00 PM

$ALDX just kidding i m here for 9-12-16 whatever

0 · Reply

GoldmanSlaps Oct. 3 at 8:00 PM

$ALDX

0 · Reply

CharlieeMungerTWITS Oct. 3 at 7:50 PM

$KURA $ALDX $CORT $AGIO all bio with catalysts impending winners

0 · Reply

jaxon613 Oct. 3 at 7:34 PM

$ALDX I never understand why people freak out or get over excited when this stock does this it's the same every time

2 · Reply

Motohead125 Oct. 3 at 6:06 PM

$ALDX that's the spot, harder, faster

0 · Reply

Milanfinest Oct. 3 at 5:19 PM

$ALDX ..

0 · Reply

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:01 AM EDT - 5 weeks ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 19, 2025, 7:01 AM EDT - 6 weeks ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 6, 2025, 7:01 AM EDT - 2 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 24, 2025, 7:00 AM EDT - 2 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 17, 2025, 7:00 AM EDT - 2 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jul 2, 2025, 9:23 PM EDT - 3 months ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Jun 26, 2025, 7:00 AM EDT - 3 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

May 29, 2025, 7:01 AM EDT - 4 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:07 PM EDT - 5 months ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 5 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 4:42 PM EDT - 5 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 3:48 PM EDT - 5 months ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 5, 2025, 6:34 PM EDT - 5 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 5 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 5 months ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 5 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 5 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 5 months ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 5 months ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 9:49 AM EDT - 5 months ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 28, 2025, 9:00 PM EDT - 5 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

TTGT

Apr 28, 2025, 3:46 PM EDT - 5 months ago

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

Apr 27, 2025, 8:20 AM EDT - 5 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Apr 25, 2025, 3:22 PM EDT - 5 months ago

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

Apr 25, 2025, 7:36 AM EDT - 5 months ago

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money

Apr 24, 2025, 3:18 PM EDT - 5 months ago

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law

Apr 23, 2025, 3:36 PM EDT - 5 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law

Apr 23, 2025, 8:18 AM EDT - 5 months ago

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

Apr 22, 2025, 3:23 PM EDT - 5 months ago

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money

Apr 21, 2025, 10:52 AM EDT - 5 months ago

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

Apr 21, 2025, 8:33 AM EDT - 5 months ago

ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX)

Apr 18, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation

Apr 17, 2025, 10:00 AM EDT - 6 months ago

Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 17, 2025, 8:36 AM EDT - 6 months ago

ALDX INVESTOR INVESTIGATION: Aldeyra Therapeutics, Inc. Investors are Reminded of the Ongoing Securities Investigation – Contact BFA Law (NASDAQ:ALDX)

Apr 17, 2025, 7:00 AM EDT - 6 months ago

Aldeyra Therapeutics Appoints Chip Clark to Board of Directors

Apr 16, 2025, 4:07 PM EDT - 6 months ago

ALDX INVESTIGATION REMINDER: Aldeyra Therapeutics, Inc. Investors are Reminded of the Pending Investigation -- Contact BFA Law

Apr 16, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation

Apr 15, 2025, 3:36 PM EDT - 6 months ago

ALDX INVESTIGATION: The Aldeyra Therapeutics, Inc. Securities Investigation is Ongoing - Contact BFA Law if You Suffered Losses

Apr 15, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect

AllinDeyra Oct. 4 at 7:52 PM

$ALDX another 100% and we are back at around 12 usd 😉

0 · Reply

TheGodsMustBeCrazy Oct. 3 at 8:56 PM

$ALDX shorts are about to get a rude awakening.

1 · Reply

Traderjoe1911 Oct. 3 at 8:24 PM

2 · Reply

AllinDeyra Oct. 3 at 8:06 PM

$ALDX breaking... 6,5 USD soon..back to the 6-8 corridor

0 · Reply

Milanfinest Oct. 3 at 8:00 PM

$ALDX just kidding i m here for 9-12-16 whatever

0 · Reply

GoldmanSlaps Oct. 3 at 8:00 PM

$ALDX

0 · Reply

CharlieeMungerTWITS Oct. 3 at 7:50 PM

$KURA $ALDX $CORT $AGIO all bio with catalysts impending winners

0 · Reply

jaxon613 Oct. 3 at 7:34 PM

$ALDX I never understand why people freak out or get over excited when this stock does this it's the same every time

2 · Reply

Motohead125 Oct. 3 at 6:06 PM

$ALDX that's the spot, harder, faster

0 · Reply

Milanfinest Oct. 3 at 5:19 PM

$ALDX ..

0 · Reply

TheGodsMustBeCrazy Oct. 3 at 2:33 PM

$ALDX

1 · Reply

CharlieeMungerTWITS Oct. 3 at 2:22 PM

$ALDX LETS GO! 4% a day makes my wife Go away !!!

0 · Reply

AllinDeyra Oct. 3 at 1:49 PM

$ALDX break the 5,5 and the way up to 6-8 usd is free

0 · Reply

Milanfinest Oct. 3 at 11:40 AM

$ALDX ..

0 · Reply

CharlieeMungerTWITS Oct. 2 at 11:47 PM

$ALDX $ABBV

1 · Reply

SweepCastApp Oct. 2 at 8:20 PM

$ALDX: Unusual Options Activity Alerted CALL flow observed 1016x contracts at Strike price of $7.5 Exp on 12/19/2025 with Premium of $46K and showing BEARISH Sentiment

2 · Reply

Greene2 Oct. 2 at 7:31 PM

$ALDX Assuming success on PDUFA day. What is everyone’s thoughts on Abbvie buying Reproxalap vs buying the entire company?

4 · Reply

AllinDeyra Oct. 2 at 7:04 PM

$ALDX buy buy buy...let it breakout to go back to 5,5...then we can go to 6,5 usd and 7,5 back into the Former

0 · Reply

Statesman2024 Oct. 2 at 5:49 PM

$ALDX I heard from a reliable person at AbbVie that mgrs were going to start planning training discussions on DE soon. This is significantly different than the last time waiting on approval as there was basically no talk about training. Additionally, I’m actually hearing OD’s talking about this product vs last I wasn’t hearing it really discussed. I see this as a very good sign! I was actually thinking a late November approval…however, with the GSD who knows how it will impact the timing. As far as AbbVie buying it from ALDX I believe they will as I don’t believe they will really need anything from ALDX. AbbVie has been in this space for years and knows how to market into this space and has a wealth of KOL’s so why give up 40% IMO!

2 · Reply

Milanfinest Oct. 2 at 5:15 PM

$ALDX volumes ever pick up here? If i dump i move the book and the position is not particularly impressive..

3 · Reply

Smellmahass Oct. 2 at 3:50 AM

$ALDX Intriguing. 3rd time try. How high could it pop to knowing pdufa approvals dont move up much.

3 · Reply

Traderjoe1911 Oct. 1 at 9:30 PM

$ALDX It’s like the gift of a sure fire daily swing trade in here

0 · Reply

Market Cap	343.80M
Revenue (ttm)	0.00
Net Income (ttm)	-55.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.27

Volume	1,030,200
Avg Vol	845,508
Day's Range	N/A - N/A
Shares Out	59.90M
Stochastic %K	99%
Beta	0.83
Analysts	Strong Sell
Price Target	$8.80